Pharma channel feed – Endpoints News

Pharma channel feed

The pharma world's champion patent wall builder is called out for their 'drip-feed' strategy to safeguard the next megablockbuster franchise

5 years ago

Sanofi continuing with API spinoff despite French on-shoring push, tensions with union — Reuters

5 years ago

In anticipation of PhIII trial results, Amicus pares down old debt with $400 million loan

5 years ago

Top biotech analyst projects a gloomy outlook for Pfizer's JAK portfolio

5 years ago

Immunomedics spells out PFS benefit of Trodelvy in mTNBC, hunting a full OK just weeks after accelerated approval

5 years ago

A little biotech slaps back at a 'criminal' short attack, vowing to pursue a prosecution of their case

5 years ago

Which drug developers offer Trump a quick, game-changing ‘solution’ as the pandemic roars back? Eli Lilly and AbCellera look to break out of the pack

5 years ago

Novartis pays $678M for kickback scheme as Vas Narasimhan tries to distance pharma giant from shady behavior

5 years ago

Novartis loses biosimilar appeal as court upholds a 31-year monopoly by Amgen's Enbrel

5 years ago

An experienced biotech is stitched together from transpacific parts, with 265 staffers and a focus on ‘new biology’

5 years ago

New standard of care? FDA hands Pfizer, Merck KGaA an OK for Bavencio in bladder cancer

5 years ago

Elias Zerhouni discusses ‘amateur hour’ in DC, the destruction of infectious disease R&D and how we need to prep for the next time

5 years ago

On a roll, Merck blazes through a new segment of the biomarker trail

5 years ago

Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra

5 years ago

Gilead opts for $3,120 US insurer price for Covid-19 drug remdesivir — but some say it should be free

5 years ago

DBV lays off employees, scales down programs after receiving no word from FDA

5 years ago

Sanofi preps another round of layoffs as new execs look to slim down the global pharma in an ongoing reorganization — report

5 years ago

After 2 delays, Zogenix nabs FDA approval for epilepsy drug, sets price at 3X its GW Pharma competitor

5 years ago

UK Supreme Court strikes down Regeneron patents, opening door for Kymab

5 years ago

What's the hard cost of a pivotal drug trial? A lot less than you might expect

5 years ago

Epizyme hits the ground running with second — and crucial — OK for Tazverik, in follicular lymphoma

5 years ago

Hours after blockbuster patent win, Mylan asks the FDA to speed up an OK to market a generic to Biogen’s Tecfidera

5 years ago

In a fresh blow, Biogen loses a big court fight with Mylan over its blockbuster Tecfidera patent

5 years ago

AbbVie-Allergan complete, but critics continue to raise anti-competitive concerns

5 years ago

First page Previous page 256 257 258259260 261 262 Next page Last page